Traditional therapeutic approaches such as chemotherapy and radiation therapy have
burdened cancer patients with onerous physical and psychological challenges …

In the past decade, chimeric antigen receptor (CAR)-T cell therapy has emerged as a
promising immunotherapeutic approach for combating cancers, demonstrating remarkable …

Chimeric antigen receptor (CAR)-modified natural killer (NK) cells show antileukemic activity
against acute myeloid leukemia (AML) in vivo. However, NK cell-mediated tumor killing is …

Natural killer (NK) cell-based immunotherapies are attracting increasing interest in the field
of cancer treatment. Early clinical trials have shown promising outcomes, alongside …

Natural killer (NK) cells have clinical potential against cancer; however, multiple limitations
hinder the success of NK cell therapy. Here, we performed unbiased functional map** of …

Multiple factors in the design of a chimeric antigen receptor (CAR) influence CAR T-cell
activity, with costimulatory signals being a key component. Yet, the impact of costimulatory …

Adoptive cell therapies engineered to express chimeric antigen receptors (CARs) or
transgenic T cell receptors (TCRs) to recognize and eliminate cancer cells have emerged as …

Natural killer (NK) cells, initially identified for their rapid virus-infected and leukemia cell
killing and tumor destruction, are pivotal in immunity. They exhibit multifaceted roles in …

Glioblastoma (GBM) is an aggressive brain cancer with limited therapeutic options. Natural
killer (NK) cells are innate immune cells with strong anti-tumor activity and may offer a …

Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable efficacy in
haematological malignancies. However, although viral vector-based methods are effective …